
    
      This is a single arm Phase 2 study of pre-operative combination immunotherapy with
      pembrolizumab and T-VEC given for 6 months prior to complete lymph node dissection for stage
      3 resectable cutaneous melanoma with clinically apparent lymph node metastases.
    
  